Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31095475 | 1.00 | CHUK (0.38) | CHUKCHEK1HSP90AA1HSP90AB1PDK2 | |
| SCHEMBL25047586 | 0.84 | KDM4E (0.33) | CHUKHSP90AA1HSP90AB1KMO | |
| SCHEMBL1738453 | 0.81 | CHUK (0.58) | CHUKCHEK1HSP90AA1HSP90AB1 | |
| SCHEMBL10185949 | 0.79 | HSP90AB1 (0.39) | CHUKHSP90AB1 | |
| SCHEMBL1900144 | 0.79 | HSP90AB1 (0.42) | CHUKHSP90AB1 | |
| SCHEMBL2594685 | 0.79 | CHUK (0.40) | CHUKCHEK1HSP90AA1HSP90AB1 | |
| SCHEMBL1018453 | 0.78 | CHUK (0.39) | CHUKCHEK1 | |
| SCHEMBL11918007 | 0.77 | CHUK (0.30) | CHUKKMO | |
| SCHEMBL1017679 | 0.76 | CHUK (0.41) | CHUKCHEK1 | |
| SCHEMBL1017711 | 0.76 | CHEK1 (0.56) | CHUKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656249-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| US-20250019385-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-01-16 | — | — | US | disclosed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| CN-110913855-B | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-3478687-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2024-03-20 | — | — | EP | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | AXL, FLT3, TYRO3 | CHUK 251/4885CHEK1 182/4885HSP90AA1 1507/4885 |
| US-20250019385-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, RB1 | CHUK 784/4885CHEK1 99/4885HSP90AA1 2019/4885 |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | CHUK 39/4885CHEK1 1344/4885HSP90AA1 2811/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | CHUK 846/4885CHEK1 879/4885HSP90AA1 1571/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | CHUK 39/4885CHEK1 1344/4885HSP90AA1 2811/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | CHUK 39/4885CHEK1 1344/4885HSP90AA1 2811/4885 |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | CHUK 13/4885CHEK1 607/4885HSP90AA1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.